ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,057.55
1.25%
S&P 500
5,296.79
-0.01%
Dow Jones
39,915.40
0.12%
US Dollar vs Yen
155.7475
0.23%
Brent Oil
83.145
-0.07%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Kiniksa Pharmaceuticals Ltd (KNSA)

  7. Kiniksa Pharmaceuticals Ltd (KNSA) ニュース

KNSA

Kiniksa Pharmaceuticals (KNSA)

Kiniksa Pharmaceuticals Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KNSA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0805 : 01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/04/2320 : 30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/04/1705 : 01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/04/0220 : 30GlobeNewswire Inc.Kiniksa Pharmaceuticals Announces Development Indication for AbiprubartNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/03/0606 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/03/0606 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/03/0207 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/03/0106 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/2821 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/2821 : 30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/2807 : 06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/2206 : 01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/1506 : 39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/02/1505 : 46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/01/0506 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/01/0421 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/01/0421 : 30GlobeNewswire Inc.Kiniksa Pharmaceuticals Provides Corporate UpdateNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/01/0406 : 55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2024/01/0306 : 01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/12/1206 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/12/0806 : 46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/11/0305 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/10/3120 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/10/3120 : 30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/10/2505 : 01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/09/0708 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/09/0708 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/09/0708 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/09/0708 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
2023/09/0606 : 26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:KNSA

最近閲覧した銘柄

NYSE
TDS-V
Telephone and Data Systems
KUCN
WGPUSDT
W GREEN PAY
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有